Acute Lung Injury Market

Market Overview:

The 7 major acute lung injury markets reached a value of US$ 3.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.8 Billion by 2034, exhibiting a growth rate (CAGR) of 3.61% during 2024-2034.

The acute lung injury market has been comprehensively analyzed in IMARC's new report titled "Acute Lung Injury Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute lung injury (ALI) is a medical condition characterized by inflammation of the lungs that prevents them from supplying enough oxygen to the body's organs. Some common symptoms of the ailment include shortness of breath, low oxygen levels, coughing, chest pain, etc. Patients with ALI may also experience fatigue, confusion, and a bluish tint on their skin or lips. In more severe cases, ALI can lead to acute respiratory distress syndrome (ARDS). The disease diagnosis primarily involves a combination of physical examination, medical history, and diagnostic testing. The healthcare provider will typically start by assessing the patient's breathing, oxygen levels, and other vital signs. They may also perform several imaging tests, such as chest X-rays or CT scans, to look for indications of inflammation or fluid buildup in the lungs. Furthermore, blood tests are used to measure oxygen levels and check for signs of infection or other underlying conditions that may be contributing to the patient's symptoms.

The rising incidence of severe infections that cause inflammation in the lungs is primarily driving the acute lung injury market. In addition to this, the increasing prevalence of several associated risk factors, such as pneumonia, aspiration, inhalation of toxic substances, etc., is also augmenting the market growth. Moreover, the widespread adoption of lung-protective ventilation strategies, which aim to reduce the risk of ventilator-induced lung injury, is creating a positive outlook for the market. These strategies typically utilize low tidal volumes and limit the inspiratory plateau pressure. Apart from this, the escalating utilization of neuromuscular blockers, which work by paralyzing the patient's muscles and improving oxygenation, to facilitate mechanical ventilation in patients with ALI is further bolstering the market growth. Additionally, the emerging popularity of positive end-expiratory pressure (PEEP) titration, due to its numerous benefits, including improved oxygenation, reduced need for higher FiO2 levels, and minimized risk of ventilator-associated lung injury, is also propelling the market. Besides this, several key players are making extensive investments to identify specific biomarkers, such as interleukin-6 (IL-6) and surfactant protein-D (SP-D), which can assist in predicting the onset of ALI and its severity. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the increasing utilization of extracorporeal support, including extracorporeal membrane oxygenation (ECMO) and extracorporeal carbon dioxide removal (ECCO2R), for improving survival rates in patients with ALI, particularly those with more advanced stages, is expected to drive the acute lung injury market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the acute lung injury market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute lung injury and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute lung injury market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute lung injury market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute lung injury market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute lung injury marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the acute lung injury market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute lung injury market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute lung injury market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acute lung injury across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute lung injury by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute lung injury by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acute lung injury across the seven major markets?
• What is the size of the acute lung injury patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute lung injury?
• What will be the growth rate of patients across the seven major markets?
   

Acute Lung Injury: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute lung injury drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute lung injury market?
• What are the key regulatory events related to the acute lung injury market?
• What is the structure of clinical trial landscape by status related to the acute lung injury market?
• What is the structure of clinical trial landscape by phase related to the acute lung injury market?
• What is the structure of clinical trial landscape by route of administration related to the acute lung injury market?